Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Innovation Drives High-Quality Development: Dr. Jin Fang, Chief Scientist of Health Yuan, Attends the First Session of the 14th National People's Congress

Published Time:

2023-03-10

The 2023 Government Work Report pointed out the need to effectively guarantee the public's access to medical care and medicine, safeguarding people's lives and health. This has once again brought the promotion of domestic innovative drug development into focus. Dr. Jin Fang, Chief Scientist of Healthyuan Pharmaceutical Group, attended the first session of the 14th National People's Congress as a national deputy. 。

 

Dr. Jin Fang, National People's Congress deputy and Chief Scientist of Healthyuan.

 

Representative Jin Fang has been deeply engaged in the R&D of respiratory drugs and the industrialization of high-end complex inhalation formulations for more than 30 years. With her professional dedication and pursuit of excellence, she has broken through the technological monopoly and 'bottleneck' barriers of a few multinational pharmaceutical companies internationally. 'For health, for tomorrow, wholeheartedly making good medicine and new medicine'. This is the mission and vision, and a series of innovative achievements have been made in the field of respiratory medication.

 

Representative Jin Fang stated, COPD is one of the diseases with the highest incidence and mortality rates worldwide, Most COPD patients, even when they perceive physical discomfort, do not actively seek medical attention, further missing the opportunity for treatment. Currently, there are more than 100 million COPD patients in China, but the public awareness of the disease is less than 5%. Although the Chronic Respiratory Disease Action Plan has been listed as one of the major actions in the Healthy China 2030 initiative, it has not yet been included in the national basic public health service program and has not yet received widespread social attention. Therefore, it is hoped that support can be provided for research on early intervention of COPD, and that public education can be carried out throughout society to raise public awareness. Next, she will continue to work with her team to explore and research new drugs, continuously developing more new and good drugs needed by the public, promoting the high-quality development of domestic biomedicine, and showcasing the strong potential of Chinese pharmaceutical companies to the world.